Egalet (NASDAQ:EGLT), a pharmaceutical company, said data from a series of Category 1 studies demonstrate that its OXAYDO pain relief tablets resist syringeability, which could potentially deter abuse through the intravenous route. Studies showed that OXAYDO forms a highly viscous gel that resisted preparation for injection and attempts to isolate oxycodone after manipulation, the company said. The data also demonstrated that the extraction of oxycodone from the tablets was significantly more difficult than from the comparator, a generic immediate-release oxycodone. OXAYDO is indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate. It is designed to discourage intranasal abuse through its patented formulation, Egalet said.
About 188,376 shares traded hands. Egalet Corp (NASDAQ:EGLT) has declined 11.58% since February 8, 2016 and is downtrending. It has underperformed by 28.06% the S&P500.
Egalet Corporation is a specialty pharmaceutical company. The company has a market cap of $195.14 million. The Firm is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. It currently has negative earnings. The Company’s products include OXAYDO and SPRIX Nasal Spray.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.